Kos Invests in Fathom Therapeutics’ AI Drug Discovery Platform
Kos Biotechnology Partners has invested in Fathom Therapeutics as part of the drug design company’s oversubscribed $55 million Series A financing. The funding will support Fathom’s platform, which combines quantum chemistry, physics based molecular simulations and artificial intelligence to develop small molecule medicines.
- Kos invested through its Kos BioVentures life sciences fund.
- Fathom’s Series A financing totaled $55 million and was led by Sutter Hill Ventures.
- Fathom’s Microcosmos platform combines physics based simulations and AI.
- The platform predicts protein and drug molecule interactions at atomic resolution.
- Fathom plans to scale its platform, advance its internal pipeline and expand partnerships.
Investment backs Fathom’s Series A
The investment was made through Kos BioVentures, the inaugural life sciences fund of Kos Biotechnology Partners. Sutter Hill Ventures led the financing, alongside other investors. Kos said the transaction strengthens its portfolio of life sciences companies and supports its strategy of backing therapeutic technologies, drug discovery platforms and biopharmaceutical businesses.
Kos Biotechnology Partners is based in New York and Athens, Greece. Founded by Dr. Simos Simeonidis and Alex Tzoukas, the firm manages $125 million in assets and invests across all stages of development in therapeutic breakthroughs, biodefense and tech enabled pharma services.
Microcosmos combines physics and AI
Fathom Therapeutics is developing its proprietary Microcosmos platform to predict how proteins move and interact with drug molecules at atomic resolution. The company combines advanced physics based simulations with AI, aiming to provide a computational approach to discovering and developing next generation small molecule medicines.
Fathom was founded by computational scientists led by Chief Executive Officer Dr. Huafeng Xu. Its co founders also include Yujie Wu, PhD, Chief Technology Officer, and Jesús Izaguirre, PhD, Chief Computational Scientist. The team’s work spans molecular simulation, computational chemistry and drug discovery, and includes scientists behind the Anton supercomputer and computational methods for predicting protein drug interactions.
According to Kos co founder and Managing Partner Dr. Simos Simeonidis, Fathom brings together expertise in “quantum chemistry and artificial intelligence.” He said the ability to model molecular interactions could help address biological targets that have historically been considered undruggable.
Fathom plans to advance its platform and pipeline
Fathom Chief Executive Officer Dr. Huafeng Xu said the company welcomed Simos Simeonidis, Alex Tzoukas and the Kos team to its investor group as it works to develop innovative therapeutics. Kos Managing Partner Alex Tzoukas said the investment would support Fathom as it scales its platform, advances its internal pipeline and expands strategic partnerships.
The companies presented the financing as support for a drug discovery model that connects computational science, AI and experimental biology. Kos said Fathom’s platform has demonstrated early results, while its investment reflects a belief that technologies improving drug discovery productivity and addressing previously inaccessible targets can create value for patients and investors. The source does not disclose specific drug candidates, therapeutic areas or clinical development milestones.
